CHR Verviers
- Address
- lock Available on a paid plan
Digestive System Diseases
The oncology unit at CHR Verviers is conducting trials that target cancers of the digestive system.
These clinical trials aim to evaluate novel therapeutic approaches and improve patient outcomes.
- Endometrial cancer
- Neuroendocrine tumours
The studies seek to determine whether adding targeted agents can extend survival and reduce disease progression for patients with these conditions.
Hemic and Lymphatic Diseases
Research in the blood and lymphatic sector focuses on assessing the effectiveness of emerging immunotherapies and combination regimens for hematologic malignancies.
- Relapsed/refractory multiple myeloma
- Peripheral T‑cell lymphoma
- B‑cell lymphoma subtypes
The goal is to discover treatment strategies that can achieve longer remission periods and better quality of life.
Neoplasms
The department’s broad cancer program includes trials that explore innovative treatments across several solid tumor types.
- Hormone‑receptor positive/HER2‑negative breast cancer
- Metastatic renal cell carcinoma
- Acute myeloid leukemia with NPM1 or KMT2A alterations
By testing new agents in these settings, investigators aim to improve response rates and delay disease progression.
Environment and Public Health
In addition to disease‑focused studies, the site evaluates how treatment environments influence patient health and access to care.
- Impact of supportive care on quality‑of‑life outcomes
- Health‑economic assessments of novel oncology therapies
These investigations help shape policies that ensure safe and equitable cancer care delivery.
Miscellaneous Research
Some investigations at CHR Verviers address cancer‑related questions that do not fit into a single therapeutic category, emphasizing translational science and biomarker development.
- Gene‑expression driven treatment decisions in early breast cancer
- Evaluation of maintenance strategies after first‑line therapy
The purpose is to generate insights that can be applied across multiple tumor types and improve personalized medicine.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 7 therapeutic areas and 15 of 69 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 66 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHR Verviers
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Open-Label, Randomized Study To Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Combined with Chemotherapy versus Rituximab Combined with Chemotherapy in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-2) | Regeneron Pharmaceuticals Inc. | Phase III | Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 69 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 3 | Unknown | 2023-12-22 | 2026-04-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.